Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Cardiovascular Diseases Clinical Trial

Official title:

A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04309084
• Other study ID #: CYNK-001-MM-002
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: May 12, 2020
• Est. completion date: April 30, 2023

Study information

• Verified date: February 2023
• Source: Celularity Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 29
• Est. completion date: April 30, 2023
• Est. primary completion date: January 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Subject Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject has eligible disease status:

Newly diagnosed multiple myeloma undergoing or completed induction therapy prior to undergoing first ASCT and presenting MRD positive by NGS after completion of induction therapy.

2. Subject is > 18 and = 75 years of age at the time of signing the informed consent form (ICF).

3. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

4. Subject is willing and able to adhere to the study schedule and other protocol requirements.

5. Performance status of Eastern Cooperative Oncology Group (ECOG) < 2

6. Ability to be off immunosuppressive drugs for at least 3 days prior to the CYNK-001 cell infusion. Steroids at the equivalent of no more than 5 mg prednisone per day are permissible.

7. Subjects must have autologous peripheral blood stem cell graft available in storage for additional transplant in the event of engraftment failure.

8. Female of childbearing potential (FCBP) must not be pregnant and agree to not becoming pregnant for at least 28 days following the CYNK-001. FCBP must agree to use an adequate method of contraception during the treatment period. FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).

9. Male subjects must agree to use a condom during sexual contact for at least 28 days following the CYNK-001, even if he has undergone a successful vasectomy. Subject Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

1. Subject has plasma cell leukemia.

2. Subject has non-secretory myeloma.

3. Subject has previously undergone allogeneic stem cell transplant.

4. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

5. Subject has any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he or she were to participate in the study.

6. Subject has any condition that confounds the ability to interpret data from the study.

7. Subject has a known sensitivity or allergy to lenalidomide which will limit the subject from receiving the mandatory lenalidomide maintenance as part of the study plan.

8. Subject has aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase = 2.5 x the upper limit of normal (ULN) within 7 days prior to melphalan administration. Transient abnormalities should be discussed with the medical monitor.

9. This eligibility criterion removed with Amendment 1

10. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at screening calculated using the Modification of Diet in Renal Disease Study equation. (Levey, 2006)

11. Subject has a bilirubin level > 2 mg/dL (unless subject has known Gilbert's disease) at screening.

12. Subject has had prior treatment with biologic antineoplastic agents less than 7 days before CYNK-001 infusion and at least 5 half-lives since (excludes melphalan). (Exception will be granted for monoclonal antibodies that are known to have long half-lives, in which case a minimum of 2 weeks from last dose will be required). For agents that have known AEs occurring beyond these specified days after administration, this period must be extended beyond the time during which acute AEs are known to occur. Treating physicians are encouraged to discuss cases with the Medical Monitor.

13. Subject is pregnant or breastfeeding.

14. Subject has new or progressive pulmonary infiltrates or pleural effusion large enough to be detected by chest x-ray or computerized tomography (CT) scan within 2 weeks of CYNK-001 infusion.

15. Subject has active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy.

16. Subject who is human immunodeficiency virus (HIV) positive is excluded due to increased risk of lethal infections when treated with myeloablative chemotherapy.

17. Subject has history of malignancy, other than MM, unless the subject has been free of disease for > 3 years from the date of signing the ICF. Exceptions include the

following noninvasive malignancies:

1. Basal cell carcinoma of the skin

2. Squamous cell carcinoma of the skin CYNK-001

3. Carcinoma in situ of the cervix

4. Carcinoma in situ of the breast

5. Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)

18. Subject has a history of severe asthma and is presently on chronic medications or has a history of other symptomatic pulmonary disease.

19. Untreated chronic infection or treatment of any infection with systemic antibiotics within 2 weeks prior to melphalan.

20. Subject has any other organ dysfunction (Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Grade 3 or greater) that will interfere with the administration of the therapy according to this protocol.

21. Subject has a resting left ventricular ejection fraction (LVEF) of < 35% obtained by echocardiography or multigated acquisition scan (MUGA).

22. Subject was treated with an investigational product no less than 28 days before CYNK-001 infusion. Subject must no longer be a participant in the previous interventional study at the time of the CYNK-001 infusion. (Subjects who are under survival follow-up or observation associated with a study are permitted, and if treatment information is collected for this period, "Investigational Study" must be used for capturing the study treatment.)

Related Conditions & MeSH terms

• Analgesics
• Analgesics, Non-Narcotic
• Antineoplastic Agents
• Blood Coagulation Disorders
• Blood Protein Disorders
• Cardiovascular Diseases
• Disease
• Hematologic Diseases
• Hemorrhagic Disorders
• Hemostatic Disorder
• Hemostatic Disorders
• Immune System Diseases
• Immunoproliferative Disorders
• Lymphoproliferative Disorders
• Multiple Myeloma
• Neoplasm, Plasma Cell
• Neoplasms
• Neoplasms by Histologic Type
• Neoplasms, Plasma Cell
• Paraproteinemias
• Peripheral Nervous System Agents
• Physiological Effects of Drugs
• Sensory System Agents
• Vascular Diseases

Intervention

Biological:
• CYNK-001
CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.

Locations

Country	Name	City	State
United States	Roswell Park Comprehensive Cancer Institute	Buffalo	New York
United States	Colorado Blood Cancer Institute	Denver	Colorado
United States	Tennessee Oncology	Nashville	Tennessee
United States	Washington University	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Celularity Incorporated

Country where clinical trial is conducted

United States, 

References & Publications (1)

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004. Erratum In: Ann Intern Med. 2008 Oct 7;149(7):519. Ann Intern Med. 2021 Apr;174(4):584. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-Limiting Toxicity (DLT)	Safety Assessment of Dose-Limiting Toxicity (DLT)	Up to 28 days
Primary	Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD)	Safety Assessment of MTD OR MPD	Up to 28 days
Primary	Adverse Events (AE)	Safety Assessment of AE's	Up to 12 months
Primary	Rate of Minimal Residual Disease (MRD) Negativity	Efficacy Assessment of MRD	Day 90-100
Secondary	Minimal Residual Disease (MRD) Response	Efficacy Assessment of MRD	Day 90-100
Secondary	Time to MRD Response	Efficacy Assessment of MRD	up to 12 months
Secondary	International Myeloma Working Group (IMWG) response	Efficacy Assessment of response	up to 12 months
Secondary	duration of clinical response	Efficacy Assessment of response	up to 12 months
Secondary	Progression-free survival	Efficacy Assessment of response	up to 12 months
Secondary	time to progression	Efficacy Assessment of response	up to 12 months
Secondary	overall survival	Efficacy Assessment of response	up to 12 months
Secondary	Quality of life questionnaire	Efficacy Assessment of response	up to 12 months